Pharmaceutical R&D Services
- Preclinical Evaluation Services
- ADME/DMPK for Stroke Drugs
- Drug Efficacy Testing for Stroke
- Cerebral Infarct Size Measurement
- Histological Assessment
- Physiological Monitoring
- Behavioral Testing
- Brain Imaging
- Fluorescence Imaging (FI)
- Bioluminescence Imaging (BLI)
- Magnetic Resonance Imaging (MRI)
- Photoacoustic Imaging (PAI)
- Laser Speckle Contrast Imaging (LSCI)
- Functional Ultrasound Imaging
- Micro-computed Tomography (Micro-CT) Imaging
- Positron Emission Tomography (PET) Imaging
- Single-photon Emission Computed Tomography (SPECT) Imaging
- Cerebral Blood Flow Monitoring
- Brain Edema Measurement
- Assessment of Blood-Brain Barrier
- Assessment of Leukocyte-Platelet Aggregates
- Quantitative Analysis of Protein and mRNA Expression
- Measurement of Peri-Infarct Dendritic Spine Turnover After Stroke
- Imaging of Microglia Activation in Animal Models of Stroke
- Calcium Imaging of Neuronal Activity in Stroke
- Safety Assessment for Stroke Drugs
- In Vitro Pharmacology for Stroke Drugs
- Pathogenic Mechanism Analysis
- Analysis of Ischemia-Triggered Glutamate Excitotoxicity
- Molecular Mechanism Analysis of Oxidative Stress in Stroke
- Analysis of Neuroinflammatory Mechanisms in Stroke
- Molecular Mechanism Analysis of Ischemia-Reperfusion Injury
- Cell Death Mechanism Analysis in Stroke
- Epigenetic Mechanism Analysis in Stroke
- Analysis of Gut Microbiota in Stroke
- Customized Stroke Models
- Animal Modeling of Stroke
- Animal Modeling of Ischemic Stroke
- Custom Four-Vessel Occlusion (4-VO) Model of Global Ischemic Stroke
- Custom Two-Vessel Occlusion (2-VO) Model of Global Ischemic Stroke
- Custom Complete Global Brain Ischemia Models
- Custom Endovascular Filament Model of Middle Cerebral Artery Occlusion (MCAO)
- Custom Middle Cerebral Artery Occlusion (MCAO) Model by Transcranial Electrocoagulation
- Custom Embolic Stroke Models
- Custom Endothelin-1 (ET-1) Induced Ischemic Stroke Model
- Custom Photothrombotic Stroke Model
- Custom Ferric Chloride-Induced Arterial Thrombosis Model
- Animal Modeling of Hemorrhagic Stroke
- Animal Modeling of Ischemic Stroke
- In Vitro Modeling of Stroke
- Animal Modeling of Stroke
- Stroke Drug Development Services
- By Drug Modality
- By Drug Action
- Neuroprotective Agents Against Stroke
- Glutamate Receptor Antagonists
- Free-radical Scavengers and Antioxidants
- Ion Channel Modulators
- Anti-inflammatory Stroke Therapies
- GABA Receptor Agonists
- PSD-95 Inhibitors
- Magnesium Therapies
- Endothelin Receptor Agonists
- C-Jun N-terminal Kinase Inhibitors
- Small Molecule Erythropoietin Mimetics
- Albumin Therapies
- PPAR Agonists
- Matrix Metalloproteinase Inhibitors
- Blood Glutamate Scavengers
- Signal Transduction Modulators
- Thrombolytics for Stroke
- Anticoagulant Drugs
- Antiplatelet Drugs for Stroke
- Neuroprotective Agents Against Stroke
- Customized Biospecimen Collection and Analysis Services
- Stroke Biomarker Development Services
- Drug Delivery System Development for Stroke
Online Inquiry
Fig. 1. Modeling ICH in mice. (Sansing et al., 2011)